Spots Global Cancer Trial Database for EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer
Official Title: An Open-label, Randomized, Controlled, Multicenter, Phase I/II Trial Investigating 2 EMD 525797 Doses in Combination With Cetuximab and Irinotecan Versus Cetuximab and Irinotecan Alone, as Second-line Treatment for Subjects With K-ras Wild Type Metastatic Colorectal Cancer (mCRC)
Study ID: NCT01008475
Conditions
Study Description
Brief Summary: The purpose of this study is to assess the safety and clinical activity of the experimental drug EMD 525797 (study drug), a monoclonal antibody targeting alfa integrins, in combination with irinotecan and cetuximab in K-ras wildtype metastatic colorectal cancer patients.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
Research Site, Brussels, , Belgium
Research Site, Edegem, , Belgium
Research Site, Gent, , Belgium
Research Site, Leuven, , Belgium
Research Site, Sofia, , Bulgaria
Research Site, Strovolos, Nicosia, Cyprus
Research Site, Brno, , Czech Republic
Research Site, Horovice, , Czech Republic
Research Site, Kutna Hora, , Czech Republic
Research Site, Olomouc, , Czech Republic
Research Site, Pardubice, , Czech Republic
Research Site, Prague, , Czech Republic
Research Site, Dresden, , Germany
Research Site, Essen, , Germany
Research Site, Freiburg, , Germany
Research Site, Hamburg, , Germany
Research site, Hannover, , Germany
Research Site, Heilbronn, , Germany
Research Site, Landshut, , Germany
Research Site, Leipzig, , Germany
Research Site, Munich, , Germany
Research Site, Recklinghausen, , Germany
Research Site, Ulm, , Germany
Research Site, Thessaloniki, Cyprus, Greece
Research Site, Mournies Chania, , Greece
Research Site, Budapest, , Hungary
Research Site, Gyor, , Hungary
Research Site, Kecskemet, , Hungary
Research Site, Miskolc, , Hungary
Research Site, Nyiregyhaza, , Hungary
Research Site, Szolnok, , Hungary
Research Site, Haifa, , Israel
Research Site, Jerusalem, , Israel
Research Site, Ramat Gan, , Israel
Research Site, Rechovot, , Israel
Research Site, Tel-Aviv, , Israel
Research Site, Elblag, , Poland
Research Site, Gdańsk, , Poland
Research Site, Gliwice, , Poland
Research Site, Rybnik, , Poland
Research Site, Warszawa, , Poland
Research Site, Łódź, , Poland
Research, Arkhangelsk, , Russian Federation
Research Site, Moscow, , Russian Federation
Research Site, Novosibirsk, , Russian Federation
Research Site, Omsk, , Russian Federation
Research Site, St. Petersburg, , Russian Federation
Research Site, Tomsk, , Russian Federation
Research Site, Barcelona, , Spain
Research Site, Elche, , Spain
Research Site, Madrid, , Spain
Research Site, Mallorca, , Spain
Research Site, Santander, , Spain
Research Site, Santiago de Compostela, , Spain
Research Site, Terrassa, , Spain
Research Site, Valencia, , Spain
Research Site, Aberdeen, , United Kingdom
Research Site, Glasgow, , United Kingdom
Research Site, London, , United Kingdom
Research Site, Manchester, , United Kingdom
Research Site, Nottingham, , United Kingdom
Research Site, Sutton, , United Kingdom
Contact Details
Name: Medical Responsible
Affiliation: Merck KGaA, Darmstadt, Germany
Role: STUDY_DIRECTOR
Name: Prof. Josep Tabernero
Affiliation: HU Vall d' Hebron, Servei d'oncologia. E difici General
Role: PRINCIPAL_INVESTIGATOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
